Tagrisso demonstrated 5 5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer astrazeneca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from astrazeneca.com Daily Mail and Mail on Sunday newspapers.
Nearly three in four patients treated with adjuvant TAGRISSO were alive and disease-free at four years
Exploratory results showed TAGRISSO also reduced the risk of disease recurrence in the brain or spinal cord by 76% in patients with Stage II-IIIA disease
Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Tagrisso adjuvant receives positive CHMP opinion investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
of patients with early-stage EGFR-mutated lung cancer Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China where Tagrisso reduced the risk of disease recurrence or death by 80%
AstraZeneca s Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent, with or without adjuvant chemotherapy as recommended by the patient s physician. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations.